AKRO insider transaction filings
Akero Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-09. Screen AKRO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-09 | 4 | Heyman Tomas J. — Director | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) | EDGAR |
| 2025-12-09 | 4 | Xu Yuan — Director | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 26,000 (derivative) | EDGAR |
| 2025-12-09 | 4 | Cheng Andrew — President and CEO, Director | Disposition to issuer (D): 277,075 · Disposition to issuer (D): 159,762 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 5,032 (derivative) · Disposition to issuer (D): 2,328 (derivative) · Disposition to issuer (D): 4,739 (derivative) · +10 more | EDGAR |
| 2025-12-09 | 4 | Graham G. Walmsley — Director | Disposition to issuer (D): 93,000 · Disposition to issuer (D): 1,200,000 · Disposition to issuer (D): 9,398 · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2025-12-09 | 4 | Judy Chou — Director | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 26,000 (derivative) | EDGAR |
| 2025-12-09 | 4 | Rolph Timothy — Chief Scientific Officer | Disposition to issuer (D): 238,339 · Disposition to issuer (D): 43,810 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 5,032 (derivative) · Disposition to issuer (D): 2,328 (derivative) · Disposition to issuer (D): 56,579 (derivative) · +7 more | EDGAR |
| 2025-12-09 | 4 | White William Richard — Chief Financial Officer | Disposition to issuer (D): 10,179 · Disposition to issuer (D): 47,573 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 5,032 (derivative) · Disposition to issuer (D): 2,328 (derivative) · Disposition to issuer (D): 4,739 (derivative) · +12 more | EDGAR |
| 2025-12-09 | 4 | Yale Catriona — Chief Development Officer | Disposition to issuer (D): 27,227 · Disposition to issuer (D): 47,573 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 5,032 (derivative) · Disposition to issuer (D): 2,328 (derivative) · Disposition to issuer (D): 70,279 (derivative) · +5 more | EDGAR |
| 2025-12-09 | 4 | Lamy Patrick — See Remarks | Disposition to issuer (D): 3,059 · Disposition to issuer (D): 26,832 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 382 (derivative) · Disposition to issuer (D): 11,096 (derivative) · Disposition to issuer (D): 48,679 (derivative) · +2 more | EDGAR |
| 2025-12-09 | 4 | Young Jonathan — Chief Operating Officer | Disposition to issuer (D): 152,616 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 47,573 · Disposition to issuer (D): 3,421 (derivative) · +10 more | EDGAR |
| 2025-12-09 | 4 | Gangloff Scott A. — Chief Technology Officer | Disposition to issuer (D): 5,088 · Disposition to issuer (D): 21,263 · Disposition to issuer (D): 17,784 (derivative) · Disposition to issuer (D): 73,700 (derivative) · Disposition to issuer (D): 204,616 (derivative) | EDGAR |
| 2025-12-09 | 4 | Henderson Jane — Director | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · +1 more | EDGAR |
| 2025-12-09 | 4 | Iwicki Mark T — Director | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · +3 more | EDGAR |
| 2025-12-09 | 4 | Harrison Seth Loring — Director | Disposition to issuer (D): 136,301 · Disposition to issuer (D): 148,063 · Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · +3 more | EDGAR |
| 2025-11-28 | 4 | Rolph Timothy — Chief Scientific Officer | Option exercise (M): 3,527 @ $28.35 · Option exercise (M): 43,064 @ $6.36 · Option exercise (M): 4,284 @ $21.09 · Option exercise (M): 2,796 @ $0.61 · Option exercise (M): 94,268 @ $0.61 · Option exercise (M): 4,739 @ $21.10 · +6 more | EDGAR |
| 2025-11-26 | 4 | Young Jonathan — Chief Operating Officer | Option exercise (M): 4,284 @ $21.09 · Option exercise (M): 3,527 @ $28.35 · Option exercise (M): 4,739 @ $21.10 · Gift (G): 9,259 @ $0 · Option exercise (M): 4,284 (derivative) @ $0 · Option exercise (M): 3,527 (derivative) @ $0 · +1 more | EDGAR |
| 2025-11-21 | 4 | Cheng Andrew — President and CEO, Director | Gift (G): 74,538 @ $0 | EDGAR |
| 2025-11-19 | 4 | Rolph Timothy — Chief Scientific Officer | Gift (G): 37,100 @ $0 | EDGAR |
| 2025-11-13 | 4 | Cheng Andrew — President and CEO, Director | Gift (G): 14,739 @ $0 | EDGAR |
| 2025-11-06 | 4 | Yale Catriona — Chief Development Officer | Option exercise (M): 3,527 @ $28.35 · Option exercise (M): 4,739 @ $21.10 · Option exercise (M): 3,527 (derivative) @ $0 · Option exercise (M): 4,739 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | Cheng Andrew — President and CEO, Director | Option exercise (M): 30,000 @ $19.87 · Sale (S): 30,000 @ $53.98 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | Graham G. Walmsley — Director | Option exercise (M): 26,000 @ $23.02 · Option exercise (M): 15,000 @ $8.13 · Option exercise (M): 13,000 @ $26.32 · Option exercise (M): 13,000 @ $25.20 · Option exercise (M): 23,832 @ $19.97 · Option exercise (M): 26,000 (derivative) @ $0 · +4 more | EDGAR |
| 2025-10-09 | 4 | Rolph Timothy — Chief Scientific Officer | Option exercise (M): 12,500 @ $28.35 · Sale (S): 11,463 @ $46.01 · Sale (S): 1,037 @ $46.82 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-10-09 | 4 | Cheng Andrew — President and CEO, Director | Option exercise (M): 52,212 @ $0.61 · Option exercise (M): 52,212 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Young Jonathan — Chief Operating Officer | Option exercise (M): 12,500 @ $21.10 · Sale (S): 8,299 @ $47.64 · Sale (S): 4,201 @ $47.98 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Young Jonathan — Chief Operating Officer | Sale (S): 586 @ $43.02 | EDGAR |
| 2025-09-12 | 4 | Yale Catriona — Chief Development Officer | Sale (S): 659 @ $43.02 | EDGAR |
| 2025-09-12 | 4 | White William Richard — Chief Financial Officer | Sale (S): 659 @ $43.02 | EDGAR |
| 2025-09-12 | 4 | Rolph Timothy — Chief Scientific Officer | Sale (S): 553 @ $43.02 | EDGAR |
| 2025-09-12 | 4 | Cheng Andrew — President and CEO, Director | Option exercise (M): 13,022 @ $6.36 · Option exercise (M): 1,919 @ $19.87 · Sale (S): 22,525 @ $42.99 · Sale (S): 7,317 @ $43.99 · Sale (S): 158 @ $44.62 · Sale (S): 1,796 @ $43.02 · +2 more | EDGAR |
| 2025-09-10 | 4 | Rolph Timothy — Chief Scientific Officer | Option exercise (M): 7,044 @ $21.09 · Option exercise (M): 5,161 @ $6.36 · Option exercise (M): 295 @ $28.35 · Sale (S): 12,466 @ $44.17 · Sale (S): 34 @ $44.88 · Option exercise (M): 7,044 (derivative) @ $0 · +2 more | EDGAR |
| 2025-09-04 | 4 | Young Jonathan — Chief Operating Officer | Option exercise (M): 12,500 @ $21.10 · Sale (S): 9,700 @ $45.78 · Sale (S): 2,739 @ $47.14 · Sale (S): 61 @ $47.58 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | Gangloff Scott A. — Chief Technology Officer | Option exercise (M): 2,600 @ $19.62 · Option exercise (M): 2,600 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Young Jonathan — Chief Operating Officer | Option exercise (M): 12,500 @ $21.10 · Sale (S): 11,151 @ $47.72 · Sale (S): 1,349 @ $48.32 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Cheng Andrew — President and CEO, Director | Sale (S): 10,795 @ $48.07 · Sale (S): 18,805 @ $48.87 · Sale (S): 400 @ $49.44 | EDGAR |
| 2025-08-12 | 4 | Henderson Jane — Director | Option exercise (M): 3,000 @ $7.01 · Sale (S): 3,000 @ $47.46 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Rolph Timothy — Chief Scientific Officer | Option exercise (M): 12,500 @ $21.09 · Sale (S): 5,538 @ $49.06 · Sale (S): 6,962 @ $49.49 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Yale Catriona — Chief Development Officer | Option exercise (M): 10,000 @ $19.87 · Sale (S): 8,658 @ $52.87 · Sale (S): 1,342 @ $53.47 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-07-11 | 4 | Cheng Andrew — President and CEO, Director | Sale (S): 14,686 @ $50.57 · Sale (S): 15,314 @ $51.73 | EDGAR |
| 2025-07-09 | 4 | Rolph Timothy — Chief Scientific Officer | Option exercise (M): 12,500 @ $21.09 · Sale (S): 10,634 @ $50.93 · Sale (S): 1,825 @ $52.00 · Sale (S): 41 @ $52.62 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Lamy Patrick — Senior VP, Commercial Strategy | Sale (S): 2,000 @ $52.88 | EDGAR |
| 2025-07-02 | 4 | Yale Catriona — Chief Development Officer | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | Young Jonathan — Chief Operating Officer | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | Lamy Patrick — Senior VP, Commercial Strategy | Grant/award (A): 193 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | White William Richard — Chief Financial Officer | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | Rolph Timothy — Chief Scientific Officer | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | Cheng Andrew — President and CEO, Director | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-07-02 | 4 | Gangloff Scott A. — Chief Technology Officer | Grant/award (A): 299 @ $23.87 | EDGAR |
| 2025-06-20 | 4 | Cheng Andrew — President and CEO, Director | Sale (S): 6,620 @ $54.84 | EDGAR |
| 2025-06-20 | 4 | Lamy Patrick — Senior VP, Commercial Strategy | Sale (S): 875 @ $54.59 | EDGAR |
Recent 8-K events — Akero Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-12-09 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2025-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AKRO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →